Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Vanguard S&P 500 ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Vanguard S&P 500 ETF trades at $691.87. The key difference: Vanguard S&P 500 ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | VOO | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $491.22 | $698.29 |
52-Week Low | $278.09 | $571.45 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
VOO, the Vanguard S&P 500 ETF, trades at $693.83, up 0.45% today, with a bullish technical signal from moving averages and overall market sentiment. The ETF nears record highs amid strong AI-driven earnings optimism, with a dividend of $1.96 scheduled for June 2026. Key resistance lies at $699, while support holds at $681.
Outlook remains positive due to S&P 500 earnings strength and institutional inflows, but risks include Fed policy uncertainty and stretched valuations. Investors benefit from broad market exposure, though volatility may rise with economic shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
